ASBMT. abstract. Biol Blood Marrow Transplant 19 (2013) 123e128. Article history: Received 12 April 2012 Accepted 23 August 2012
|
|
- Cameron Ford
- 6 years ago
- Views:
Transcription
1 Biol Blood Marrow Transplant 19 (2013) 123e128 Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma ASBMT American Society for Blood and Marrow Transplantation Julie M. Vose 1, *, Philip J. Bierman 1, Fausto R. Loberiza 1, Charles Enke 2, Jordan Hankins 3, Robert G. Bociek 1, Wing C. Chan 4, Dennis D. Weisenburger 4, James O. Armitage 1 1 Department of Internal Medicine, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska 2 Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska 3 Department of Radiology, Section of Nuclear Medicine, University of Nebraska Medical Center, Omaha, Nebraska 4 Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska Article history: Received 12 April 2012 Accepted 23 August 2012 Key Words: Radioimmunotherapy Autologous stem cell transplantation Diffuse large B cell lymphoma 131-Iodine tositumomab abstract The purpose of this study was to evaluate the standard outpatient dose of 131-Iodine tositumomab (75 cgy) combined with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem cell rescue for the treatment of chemotherapy-sensitive relapsed or refractory, or high-risk first complete remission (CR) patients with diffuse large B cell non-hodgkin s lymphoma (DLBCL). Forty patients with chemotherapy-sensitive persistent or relapsed or high/intermediate or high international prognostic index DLCBL were treated in a phase II trial combining 75 cgy 131-Iodine tositumomab with high-dose BEAM followed by autologous stem cell transplantation. The CR rate after transplantation was 78%, and the overall response rate was 80%. Short-term and long-term toxicities were similar to historical control patients treated with BEAM alone. With a median follow-up of 6 years (range, 3-10 years), the 5-year overall survival (OS) was 72% (95% confidence interval [CI], 55%-83%), and the 5-year progression-free survival (PFS) rate was 70% (95% CI, 53%-82%). The PFS and OS were encouraging in this group of chemotherapy-sensitive persistent, relapsed, or high-risk patients with DLBCL. A follow-up phase III trial with 131-Iodine tositumomab/beam vs rituximab/beam was planned based on this information. Ó 2013 American Society for Blood and Marrow Transplantation. INTRODUCTION Standard anthracycline-containing chemotherapy regimens combined with rituximab produce a complete remission (CR) in approximately 60% to 80% of patients with diffuse large B cell lymphoma (DLBCL), which is associated with long-term disease-free survival in approximately 40% to 80% of patients depending on the patient characteristics [1-4]. Patients with persistent or recurrent DLBCL after a standard anthracycline-based regimen, rarely have long-term diseasefree survival with standard salvage chemotherapy [5]. This is particularly true in the rituximab era [6]. High-dose chemotherapy with autologous stem cell transplantation (ASCT) for patients with persistent or recurrent DLBCL can achieve longterm disease-free survival in approximately 30% to 60% of patients [7-9]. Lymphomas also demonstrate radiosensitivity in many cases, and localized radiation can be a useful adjunct to the therapy [10]. In addition, total body irradiation (TBI) has also been used as a part of conditioning regimens for stem cell transplantations [11,12]. However, results with standard high-dose chemotherapy and ASCT have not been optimized, and concerns about the use of TBI for short- and long-term side effects have led to alternative methods for transplantation preparative regimens being developed. Monoclonal Abs such as rituximab have recently been added to the transplantation preparative regimen, used Financial disclosure: See Acknowledgments on page 127. * Correspondence and reprint requests: Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris, Section of Hematology/Oncology, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE address: jmvose@unmc.edu (J.M. Vose) /$ e see front matter Ó 2013 American Society for Blood and Marrow Transplantation. before the collection of autologous stem cells, or in the posttransplantation setting as a consolidative therapy [13,14]. Additionally, several pilot trials using radioimmunotherapy either alone or in combination with highdose chemotherapy followed by ASCT have been published [15-17]. In an initial phase I study, high-dose radioimmunotherapy with 131-Iodine tositumomab followed by ASCT was administered to patients with relapsed B cell non- Hodgkin lymphoma (NHL) [15]. In subsequent studies, highdose 131-Iodine tositumomab was given with dose-intense etoposide and cyclophosphamide followed by ASCT in an attempt to substitute the 131-Iodine tositumomab for TBI in the transplantation regimen [17]. The maximum dose in the combination trial that could be administered with etoposide 60 mg/kg and cyclophosphamide 100 mg/kg was a 131- Iodine tositumomab dose of 25 Gy to critical normal organs. The preliminary results from this study were encouraging with the estimated overall survival (OS) and progression-free survival (PFS) of all treated patients at 2 years to be 83% and 68%, respectively. Because the high doses of 131-Iodine tositumomab used with this approach require specialized facilities for the administration and radiation isolation for the patients, it was difficult to perform at some centers. Subsequently, a phase I trial combining standard outpatient dosing of 131-Iodine tositumomab with high-dose chemotherapy for the treatment of resistant NHL was performed [18]. In this trial, patients with chemoresistant NHL demonstrated an unexpectedly high overall response rate of 65% with a median follow-up of 38 months, a PFS of 39%, and an OS rate of 55% [18]. Based upon the promising results in the phase I trial, this phase II trial in patients who were DLBCL transplantation
2 124 J.M. Vose et al. / Biol Blood Marrow Transplant 19 (2013) 123e Iodine Tositumomab Dosimetric Dose 131-Iodine Tositumomab Therapeutic Dose (75 cgy) Total Body Dose BEAM Chemotherapy ASCT Day -19 Day -12 Day -6 to -1 Day 0 Figure 1. Schema for 131-Iodine carmustine, etoposide, cytarabine, and melphalan (BEAM) transplantation program. recipients with chemosensitive persistent or relapsed disease was undertaken. PATIENTS AND METHODS Eligibility Patients who were age 19 to 75 years of age with persistent or relapsed DLBCL or who had high intermediate or high-risk disease by International Prognostic Index [19] were eligible. The patients needed to have a Karnofsky Performance Status of 70 to be eligible. Patients had chemotherapysensitive disease, defined as at least a 50% reduction of persistent or relapsed DLBCL according to the criteria in effect at the time of the protocol. Patients were required to have adequate cardiac and pulmonary function, defined as a left ventricular ejection fraction of 45% and a corrected carbon monoxide diffusing capacity of 50%. Additional eligibility criteria included a calculated creatinine clearance of 50 ml/min. Patients needed <20% bone marrow (BM) involvement with lymphoma. Patients needed to have BM with no evidence of myelodysplastic syndrome before entry into the protocol. In addition, the patients needed to be able to collect > CD34þ cell/kg peripheral blood progenitor cells for the transplantation. The protocol was approved by the scientific advisory board, radiation safety, and institutional review boards of the University of Nebraska Medical Center. All patients signed appropriate informed consent forms in effect for the study in accordance with the Declaration of Helsinki. Treatment Protocol: Antibody Dosimetric Dose After > CD34þ cells/kg peripheral blood progenitor cells were obtained after filgrastim mobilization, the patients received their dosimetric dose of 131-Iodine tositumomab (Figure 1). This was given on day 19 of the transplantation protocol. Orally administered saturated solution of potassium iodide with 2 drops 3 times daily was given for thyroid blockade starting 1 day before the dosimetric dose and was continued for 14 days after the therapeutic dose of 131-Iodine tositumomab. The murine monoclonal anti-cd20 (tositumomab; GlaxoSmithKline, Philadelphia, PA) was radio iodinated with sodium 131-Iodine (specific activity, 296 GBq/mg; New England Nuclear, Boston, MA) by the Iodogen method, purified, and tested as described previously [20]. Patients were premedicated with acetaminophen 650 mg and diphenhydromine 50 mg orally before the administration. Then patients received 450 mg unlabeled tositumomab i.v. followed by a trace labeled 5 mci (35 mg) 131-Iodineelabeled tositumomab dose. Vital signs were recorded every 15 minutes during the Ab administration. All dosimetric and therapeutic administrations were performed in the outpatient cancer treatment area. Within 1 hour after the dosimetric dose of 131-Iodine tositumomab and before urination, a whole body quantitative gamma camera image was obtained for baseline readings. Additional scans were performed on days 2, 3, or 4, and day 6 or 7 after the dosimetric dose. Using this information, the radioactive clearance from each patient was obtained to determine the radioactive millicurie activity of 131-Iodine tositumomab required to deliver the desired therapeutic dose 1 week later. The methodology for determining the patient-specific millicurie activity was performed in accordance with the Medical Internal Radiation Dose Primer for Absorbed Dose Calculations [21]. Therapeutic Infusions One week later, on day 12 of the transplantation protocol, the therapeutic dose of 131-Iodine tositumomab was administered on an outpatient basis. The patients were again premedicated with acetaminophen 650 mg and diphenhydramine 50 mg orally. Subsequently, 450 mg of unlabeled tositumomab was administered i.v. over 1 hour. This was followed by the patient-specific dose calculated for administration based on the whole body gamma camera images. Patients were treated with 75 cgy total body dose 131-Iodine tositumomab. The millicurie dose for the therapeutic dose was calculated based on the actual body weight for patients weighing 137% of their lean body weight and at 137% of the lean body weight for those patients weighing more than 137% of their lean body weight. Vital signs were taken every 15 minutes during the infusion of the Ab. Outpatient release criteria were used from the Nuclear Regulatory Commission guidelines [22]. These criteria authorize patient release according to a dose-based limit, which is the dose to individuals exposed to the patient (<0.5 rem). The dose-based limit addresses the public safety issue of radioactivity, which is governed by the Nuclear Regulatory Commission. High-Dose Chemotherapy Administration Starting on day 6 of the transplantation protocol, patients received carmustine 300 mg/m 2 i.v. On days 5 to 2, they received etoposide 100 mg/m 2 twice daily (8 doses total) and cytarabine 100 mg/m 2 twice daily (8 doses total) i.v., and on day 1, they received melphalan 140 mg/m 2 once i.v. The following day (day 0), the patients received their previously collected unpurged autologous peripheral blood progenitor cells. The patients received hematopoietic growth factors with filgrastim (neupogen, granulocyte colony-stimulating factor) 5 ug/kg subcutaneously starting on day þ7 after the transplantation and continuing until the absolute neutrophil count was 500/mm 3 for 3 consecutive days. Patients received 2 units of irradiated packed RBCs if their hemoglobin was 8 gm/dl and a singledonor irradiated platelet count if their platelet count was <10,000/uL. In addition, they received standard broad-spectrum antibiotic therapy for associated neutropenic fever and antifungal antibiotics for persistent fevers according to a standard transplantation protocol. Evaluation of Toxicity Toxic effects were assessed by using the National Cancer Institute Common Toxicity Criteria, version 3 [23]. Follow-Up Patients were staged for their extent of lymphoma before the stem cell transplantation, at day þ100 after the transplantation, at yearly intervals posttransplantation, and as clinically appropriate. Patients underwent computed tomography scans of the chest, abdomen, and pelvis, physical examinations, complete blood count, and chemistry profiles at these time points. In addition, if the patients had a positive BM at any point, it was repeated, and optional tests also included a positron emission tomography scan. In addition, the patients had a baseline thyroid-stimulating hormone tested, and it was repeated at day þ100 and yearly thereafter. If the patients had evidence of unexplained cytopenias, a BM biopsy for cytogenetics and analysis was obtained. Statistical Analysis The primary objective included the examination of potential efficacy with evaluation of the complete and overall remission rates (ORRs), PFS, and OS. For these purposes, the CR rate was defined as the complete disappearance of all lymph nodes previously >1.5 cm and BM negativity when previously positive. A partial response (PR) was defined as 50% reduction in the bidimensional sum of the products of all lymph nodes. Responses were evaluated according to the 1999 International Workshop Response Criteria [24]. Both PFS and OS were calculated using the Kaplan-Meier method [25]. PFS was defined as all patients who were alive at last follow-up with no documented relapse or progression of their disease. OS was defined as all patients who were alive at their last follow-up whether their disease had progressed or not. A priori power calculations showed that using PFS as the endpoint, assuming an improvement from 40% to 80% PFS, a sample of 40 patients has power of 93% using a 2-sided alpha of RESULTS Patient Information Forty patients were entered in the study between March 2000 and September The characteristics of the patients are summarized in Table 1. The patients ranged in age from 26 to 75 years of age (median, 54 years). All patients had DLBCL, which was confirmed by central pathology review (W.C.C. and D.D.W.). Thirty-five patients (88%) had received prior rituximab, and 9 (22%) had received prior involved field irradiation. Eleven patients (28%) had received 1 prior chemotherapy regimen, 23 (58%) had received 2 prior
3 J.M. Vose et al. / Biol Blood Marrow Transplant 19 (2013) 123e Table 1 Patient Characteristics Variable No. of Patients (%) No. of patients 40 Median age in years (range) 54 (26-75) Male sex 25 (62) White race 38 (95) Prior use of rituxan 35 (88) Prior use of radiation 9 (22) No. of prior chemotherapy treatments One 11 (28) Two 23 (58) Three or more 6 (14) Type of prior chemotherapy CHOP 9 (22) R-CHOP 27 (68) Others 4 (10) Ann Arbor staging before transplantation Stage I-II 11 (28) Stage III-IV 14 (35) CR 13 (33) Unknown 2 (4) LDH > normal at transplantation 13 (32) BM involvement at transplantation 1 (2) Extranodal involvement at transplantation 11 (28) Disease stage at transplantation First CR 13 (33) Primary induction failure - chemosensitive 5 (12) Relapse - chemosensitive 22 (55) Median time from diagnosis to transplantation in 15 (5-200) months (range) Less than 1 year 15 (38) Greater than or equal to 1 year 25 (62) Year of transplantation (22) (35) (43) Median time to follow-up among survivors in 6.89 ( ) years (range) CHOP indicates cyclophosphamide, doxorubicin, vincristine, prednisone; R- CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; LDH, lactic dehydrogenase; BM, bone marrow. regimens, and 6 (14%) had received 3 prior regimens. The status at transplantation included patients in primary induction failure (chemosensitive) (N ¼ 5), high-risk CR1 (N ¼ 13), and chemosensitive relapsed disease (N ¼ 22). Toxicity The grade III and IV toxicities are listed in Table 2. All patients had the expected grade III/IV hematologic toxicities severe myelosuppression (neutrophils < /L and platelets < /L) during transplantation. However, all patients engrafted with the median time to neutrophil engraftment (the first of 3 consecutive days of /L) 10 days (range, 8-30 days), the median time to platelet independence (the first of 7 consecutive days with a platelet count 20,000/uL) was 12 days (range, þ days), and the median time to RBC transfusion independence (the first of 30 consecutive days of a hemoglobin 8 gm/dl) was 9 days (range, 8-100þ days). These were similar to 120 historical control patients receiving carmustine, etoposide, cytarabine, and melphalan (BEAM) alone in which the median time to neutrophil engraftment was 11 days (range, 9-35 days), the median time to platelet independence was 12 days (range, 9-100þ days), and the median time to RBC transfusion independence was 10 days (range, 8-100þ days). Nonhematologic toxicity was similar to controls as well, as 7 patients had a bacteremia, and 1 patient had a sepsis syndrome. Five patients had pneumonia, 4 patients had atrial Table 2 Grade III and IV Nonhematologic Toxicities Toxicity Grade III-IV Events (%) of Patients Gastrointestinal: anorexia 2 (5) Diarrhea 2 (5) Esophagitis 2 (5) Hyperbilirubinemia 1 (3) Ileus 2 (5) Nausea/vomiting 2 (5) Stomatitis 6 (16) Cardiac: atrial fibrillation 4 (10) Congestive heart failure 1 (3) Syncope 1 (3) Pulmonary: pneumonia 4 (10) Pleural effusion 1 (3) Infections: bacteremia/sepsis 8 (20) Clostridium difficile colitis 3 (8) Varicella zoster 3 (8) Renal: renal insufficiency 1 (3) Secondary malignancy - AML 2 (5) AML indicates acute myelogenous leukemia. fibrillation, and 1 patient had renal insufficiency. Three patients had grade I to II, and 6 patients had grade III to IV stomatitis. There were no deaths within the first 100 days after the transplantations. Response to Therapy The response rate was assessed at day þ100 after the transplantation. The patients were restaged with physical examination, computed tomography scans, and BM biopsy (when indicated). The CR rate was 31 of 40 (78%), and the ORR was 32 of 40 (80%). OS and PFS With a median follow-up of 6 years (range, 3-10 years), the 5-year PFS was 70% (95% confidence interval [CI] 53%-82%) (Figure 2A), and the 5-year OS was 72% (95% CI, 55%-83%) (Figure 2B). When evaluating the outcomes by pretransplantation response, the 5-year PFS for patients in CR1 was 85% (95% CI, 51-96), first PR (chemosensitive) was 100%, and for relapsed chemosensitive was 54% (95% CI, 32-72) (Figure 3). The 5-year OS for the patients in CR1 was 85% (95% CI, 52-96), first PR was 100%, and relapsed DLBCL was 63% (95% CI, 40-80). For the 10 patients who relapsed 12 months from diagnosis, the 5-year PFS was 38% compared to 58% for those who relapsed >12 months from diagnosis (P ¼.86). For the patients who relapsed 12 months from diagnosis, the 5-year OS was 58% compared to 80% for those who relapsed >12 months (P ¼.25). The causes of death included progressive lymphoma in 9 patients (69%), secondary malignancy (acute myelogenous leukemia [AML]) in 2 patients (15%), bacterial infection in 1 patient (8%), and thromboembolism in 1 patient (8%). Long-Term Complications Two patients developed myelodysplastic syndrome/aml at 13 and 58 months posttransplantation, respectively. They both died from AML. Both patients had cytogenetics abnormalities at the time of myelodysplastic syndrome development consistent with alkylating agent exposure, cumulative chemotherapy, and/or radiotherapy with monosomy 5 and monosomy 7, respectively. One additional patient developed prostate cancer, 1 patient developed anal cancer, and 1 patient developed squamous cell carcinoma of the skin. Nine
4 126 J.M. Vose et al. / Biol Blood Marrow Transplant 19 (2013) 123e128 Figure 2. (A) Progression-free survival for patients treated with 131-Iodine tositumomab/carmustine, etoposide, cytarabine, and melphalan (BEAM) and autologous stem cell transplantation (ASCT). (B) Overall survival for patients treated with 131-Iodine tositumomab/beam and ASCT. patients developed subclinical hypothyroidism requiring thyroid hormone replacement. DISCUSSION Although initial rituximab containing anthracycline chemotherapy can produce high response rates and longterm disease-free survival in a majority of patients with DLBCL, between 20% and 50% of patients either fail to go into remission or relapse after an initial response [3,4]. In addition, standard salvage chemotherapy is not felt to be curative for patients with DLBCL [5,6]. High-dose chemotherapy and ASCT has produced approximately 40% to 50% long-term survivors in patients with chemotherapy-sensitive relapsed disease [7,9]. If patients are in primary induction failure, but still have disease that is somewhat chemotherapy sensitive, the results with transplantation may be higher at a 30% PFS [8]. The addition of rituximab to the transplantation program has produced excellent long-term outcomes [13,14]. However, as all of the patients with DLBCL are now receiving rituximab as part of their initial therapy, patients who relapse do not seem to benefit from additional rituximab in the posttransplantation setting [26]. Therefore, optimization of transplantation methods is an important area of research to improve these outcomes. Radiolabeled monoclonal Abs have recently emerged as an effective new treatment for patients with relapsed B cell lymphomas [18,27]. Studies using radioimmunotherapy at nonmyeloablative doses have produced response rates of 60% to 80% for 131-Iodine and 90-Yttriumelabeled anti- CD20 Abs [18,27-29]. The median duration of responses varied from 6 to 18 months in these trials; however, some CRs have been maintained for up to 6 to 8 years [29,30]. Because myelosuppression is the major toxicity associated with radioimmunotherapy, it is an ideal candidate to combine with high-dose chemotherapy and ASCT. The majority of the early studies combining radioimmunotherapy with transplantation have included highdose myeloablative 131-Iodine tositumomab either alone [15,16] or in combination with high-dose etoposide and cyclophosphamide [17]. The single agent myeloablative regimen tested in patients with a variety of relapsed lymphomas produced OS and PFS rates of 68% and 42%, respectively [15,16]. The combination regimen of etoposide, cyclophosphamide with myeloablative 131-Iodine tositumomab, and ASCT produced OS and PFS rates of 83% and 68% in patients with chemotherapy-sensitive relapsed NHL [17]. However, a concern with these high-dose 131-Iodine myeloablative regimens is the radiation safety issues and specialized facilities necessary for the administration of these agents. High-dose 90-Yttrium ibritumomab in doses up to 15 Gy to critical organs combined with BEAM has also recently been used as part of a conditioning regimen for ASCT [31].In this study by Winter et al. [31], 44 patients were treated with this combination. With a median follow-up of 33 months for all patients, the estimated 3-year PFS and OS were 43% and 60%, respectively. In another study, high-dose 90-Yttrium ibritumomab tiuxetan was combined with high-dose etoposide mg/kg and cyclophosphamide 100 mg/kg [32]. The 90-Yttrium ibritumomab tiuxetan was delivered to a target dose of 1,000 cgy highest dose to a normal organ. In this study, with a median follow-up of 22 months, the 2-year OS and relapse-free survival rates were 92% and 78%, respectively [32]. Figure 3. (A) Progression-free survival for patients who underwent transplantation in first partial response (N ¼ 5), high-risk CR1 (N ¼ 13), or relapsed diffuse large B cell lymphoma (DLBCL) (N ¼ 22). (B) Overall survival for patients who underwent transplantation in first partial response (N ¼ 5), high-risk CR1 (N ¼ 13), and relapsed DLBCL (N ¼ 22).
5 J.M. Vose et al. / Biol Blood Marrow Transplant 19 (2013) 123e Several studies using standard dose 90-Yttrium ibritumomab tiuxetan have also been combined with the BEAM protocol (Z-BEAM) in 2 recent studies. In a study from the Groupe d Etude des Lymphomes de l Adulte group, 77 patients with chemosensitive relapsed or refractory indolent lymphoma received this protocol. The 2-year event-free survival and OS were 63% and 97%, respectively, with a good safety profile [33]. A second recent study of Z-BEAM evaluated 43 patients with relapsed CD20þ NHL. Twentytwo patients were randomized to Z-BEAM and 21 patients to BEAM alone [34]. In this small study, the 2-year OS was 91% in the Z-BEAM and 62% in the BEAM arm, respectively (P ¼.05) [34]. The trial outlined in this article was a phase II trial combining standard dose 131-Iodine tositumomab (75 cgy) with a standard BEAM transplantation protocol. A prior phase I pilot trial was conducted in patients with refractory lymphoma and had promising outcomes with a total CR rate of 57% and an ORR of 65% [18]. In the phase I study, with a follow-up of 38 months, the OS was 55%, and the event-free survival was 39%. With those encouraging results, the larger phase II study adding 75 cgy total body dose 131-Iodine tositumomab to BEAM and autologous transplantation in patients with chemotherapy-sensitive relapsed diffuse large B cell lymphoma was conducted. This preparative regimen was shown to be safe and with a promising 5-year PFS of 70% and OS of 72% in this phase II trial. However, it is difficult to compare all of these trials because of the small numbers of patients, different histologies of lymphoma in the trials, and different patient populations. A subsequent large phase III randomized study to compare 131-Iodine tositumomab/beam to rituximab/beam with standard ASCT has been subsequently performed to compare these techniques [35]. In 224 randomized patients with relapsed chemosensitive DLBCL, the 2-year PFS was 49% in the 131-Iodine tositumomab/beam arm compared to 49% in the rituximab/beam arm (P ¼.65). The 2-year OS was also not different between the 2 arms (60% and 66%, respectively) (P ¼.29). Although a large phase III trial with the use of 90-Yttrim ibritumomab has not been conducted to date, a matched-cohort analysis was done comparing Z-BEAM to TBI-based regimens [36]. In this study, the 4-year OS was better for the Z-BEAM protocol compared to the TBI-based regimens (81% vs 53%; P ¼.01). This seemed to mostly be related to higher nonrelapse mortality in the TBI group (0% compared to 15%, P <.01) [36]. The specific type of histology of NHL may be very important for the use of radioimmunotherapy as part of the transplantation regimen. The patients with indolent or mantle cell lymphomas seem to have had an improved benefit from this addition. In addition, it may be that much higher doses of radioimmunotherapy are necessary to achieve improvement in the outcome of these patients. ACKNOWLEDGMENTS Financial disclosure: The authors have nothing to disclose. This work is registered with Clinicaltrials.gov, locator: NCT REFERENCES 1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346: Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7: Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23: Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-chop to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d Etudes des Lymphomes de l Adulte. Blood. 2010;116: Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-hodgkin s lymphoma. J Clin Oncol. 1999;17: Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28: Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin s lymphoma. N Engl J Med. 1995; 333: Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-hodgkin s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19: Fenske TS, Hari PN, Carreras J, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009; 15: Sutcliffe SB, Gospodarowicz MK, Bush RS, et al. Role of radiation therapy in localized non-hodgkin s lymphoma. Radiother Oncol. 1985; 4: Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin s disease and non-hodgkin s lymphoma. J Clin Oncol. 1994;12: Gutierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-hodgkin s lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001;28: Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102: Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to highdose therapy and autologous hematopoietic cell transplantation for aggressive non-hodgkin lymphoma. Blood. 2004;103: Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329: Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti- CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346: Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine- 131-tositumomab (anti-cd20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96: Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-hodgkin s lymphoma. J Clin Oncol. 2005;23: A predictive model for aggressive non-hodgkin s lymphoma. The International Non-Hodgkin s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329: Kaminiski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-hodgkin s lymphomas. J Clin Oncol. 2001; 19: Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Reston, VA: Society of Nuclear Medicine and Molecular Imaging; Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-b1 therapy. J Nucl Med. 1998;39(8 Suppl):28S-33S. 23. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: Development/electronic_applications/docs/ctcaev3.pdf. Accessed: August 30, Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-hodgkin s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:
6 128 J.M. Vose et al. / Biol Blood Marrow Transplant 19 (2013) 123e Gisselbrecht C, Glass B, Laurent G, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. American Society of Clinical Oncology 2011 ASCO annual meeting. J Clin Oncol. 2011;29(suppl):abstract Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(þ) B-cell non-hodgkin s lymphoma. J Clin Oncol. 1999;17: Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-hodgkin s lymphoma. J Clin Oncol. 2001;19: Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109: Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non- Hodgkin lymphoma: updated results and long-term follow up of the University of Michigan experience. Blood. 2000;96: Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-hodgkin s lymphoma. J Clin Oncol. 2009;27: Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-hodgkin lymphoma. Blood. 2005;106: Decaudin D, Mounier N, Tilly H, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory lowgrade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;11: Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118: Vose JM, Carter SL, Burns LJ, et al. Randomized phase III trial of 131 iodine-tositumomab(bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/beam and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or Overall Survival (OS). Presented at the 53rd ASH Annual Meeting and Exposition December 10-13, Abstract 661. Available at: webprogram/paper39888.html. Accessed: August 30, Krishnan A, Palmer JM, Tsai NC, et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Bone Marrow Transplant. 2012;18:
Digital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2004 Follow-up results of a phase II study of ibritumomab tiuetan radioimmunotherapy in patients with relapsed or
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChapter 5. M.J. Wondergem 1, J.M. Zijlstra 1, M. de Rooij 1, O.J. Visser 1, P.C. Huijgens 1, S. Zweegman 1
Chapter 5 Improving survival in patients with transformed B-cell non Hodgkin lymphoma: consolidation with 90 Yttrium ibritumomab tiuxetan-beam and autologous stem cell transplantation M.J. Wondergem 1,
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationTositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1
Generic (Trade Name): Manufacturer: Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1 NO. 64 OCTOBER 2005 Indication: Current Regulatory Status: In the
More informationIbritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline
Evidence-based Series #6-17: Section 1 Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline M. Cheung, A.E. Haynes, A. Stevens, R.M. Meyer, K. Imrie, and the members of the Hematology Disease
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationA Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma
Evidence-based Series 6-19 EDUCATION AND INFORMATION 2013 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma The Hematology
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationMini-review Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?
(2002) 29, 183 189 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Mini-review Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?
More informationImproving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy
Biology of Blood and Marrow Transplantation 12:697-702 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0001$32.00/0 doi:10.1016/j.bbmt.2006.03.014 Improving the Efficacy
More informationTiuxetan ( 90 Y-IT) as a consolidation
Aim of the study: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in the management of DLBCL. Material and methods: Patients with primary refractory
More informationOriginal article. Introduction
Original article Annals of Oncology 15: 1504 1509, 2004 doi:10.1093/annonc/mdh391 Autologous stem-cell transplantation in diffuse large B-cell non-hodgkin s lymphoma not achieving complete response after
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationA Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by. Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial.
A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial. CRUK number C17050/A5320 William Townsend 1, Rod J
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationMonoclonal Antibody Therapy With Autologous Peripheral Blood Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Monoclonal antibodies, either as single agents or combined with chemotherapy or autologous stem cell transplantation, can be effective therapy for lymphoid malignancies. William Wolk. Elvis. Oil on canvas,
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationGa-67 scintigraphy in lymphoma patients undergoing bone marrow transplantation
54 Turkish Journal of Cancer Volume 37, No. 2, 27 Ga-67 scintigraphy in lymphoma patients undergoing bone marrow transplantation PINR ÖZGEN KIRTLI 1, ELKIS ERŞ 1, EVREN ÖZDEMİR 2, YENER KOÇ 3 Hacettepe
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities
0133-049104 ZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities Please see slides 3-7 for BOXED WARNINGS and Important Safety Information. Please see full Prescribing
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationRole of high-dose therapy in diffuse large B-cell lymphoma
Role of high-dose therapy in diffuse large B-cell lymphoma Thomas Cerny a and Daniel Betticher b ' Department Internal Medicine, Head of Oncology / Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationKey Words. Stem cell transplantation Lymphoma Non-Hodgkin s lymphoma Radioimmunotherapy Iodine-131 tositumomab Yttrium-90 ibritumomab tiuxetan
The Oncologist Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin s Lymphoma: In Pursuit of a Complete Response CHRISTIAN GISSELBRECHT, a JULIE VOSE, b AUAYPORN NADEMANEE, c ALESSANDRO M.
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationScottish Medicines Consortium
Scottish Medicines Consortium ibritumomab tiuxetan (Zevalin ) No. (171/05) Schering Health Care Ltd 8 April 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationRADIOIMMUNOCONJUGATES
RADIOIMMUNOCONJUGATES TOSITUMOMAB (BEXXAR ) I. MECHANISM OF ACTION Tositumomab and Iodine I 131 tositumomab is an antineoplastic radioimmunotherapeutic monoclonal antibody-based regimen composed of the
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More information*Please see amendment for Pennsylvania Medicaid at the
1 of 32 Number: 0659 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. I. Ibritumomab tiuxetan (Zevalin) Aetna considers radioimmunotherapy with ibritumomab tiuxetan (Zevalin)
More informationA utologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin s Lymphoma
Cancer Res Treat. 2007;39(2):54-60 A utologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin s Lymphoma Sook Hee Hong, M.D. 1, Young Seon Hong,
More informationAddress correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI
Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study Saurabh Rajguru, MD, Thorhildur
More informationThis tutorial gives an overview of Radioimmunotherapy in Non-Hodgkin s Lymphoma. After completing this tutorial, attendees will be able to:
This tutorial gives an overview of Radioimmunotherapy in Non-Hodgkin s Lymphoma. After completing this tutorial, attendees will be able to: Name the radiopharmaceutical approved by the FDA for performance
More informationThe radiolabeled monoclonal antibodies 90 Y-ibritumomab
Journal of Nuclear Medicine, published on October 17, 2007 as doi:10.2967/jnumed.107.043489 Comparison of Y-Ibritumomab Tiuxetan and I-Tositumomab in Clinical Practice Heather A. Jacene*, Ross Filice*,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFerrata Storti Foundation
Non-Hodgkin Lymphoma Articles Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-hodgkin diffuse large B-cell lymphoma: results of
More informationHIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL)
Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL) Amrita Krishnan, 1 Joycelynne M. Palmer, 2 John A. Zaia, 3 Ni-Chun Tsai, 2 Joseph Alvarnas, 1 Stephen
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationIntroduction CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-hodgkin lymphoma:
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationRadioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms
Review Nuclear Medicine Review 2007 Vol. 10, No. 2, pp. 110 115 Copyright 2007 Via Medica ISSN 1506 9680 Radioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms Wojciech Jurczak
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationThe New England Journal of Medicine
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION COMPARED WITH IN AGGRESSIVE B-CELL LYMPHOMA ALESSANDRO M. GIANNI, M.D., MARCO BREGNI, M.D., SALVATORE SIENA, M.D., CRISTINA BRAMBILLA,
More informationNon Transplant-Related Treatment Options in Follicular Lymphoma
Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related
More informationPrognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationKEYWORDS: Aggressive lymphoma, High-dose therapy, Autologous stem cell transplant, Immunochemotherapy INTRODUCTION
Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of a Phase II GOELAMS Study Marie-Sarah Dilhuydy, 1 Thierry
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationORIGINAL ARTICLE. So Yeon Jeon 1,2,*, Ho-Young Yhim 1,2,*, Hee Sun Kim 3, Jeong-A Kim 4, Deok-Hwan Yang 5, and Jae-Yong Kwak 1,2
ORIGINAL ARTICLE Korean J Intern Med 218;33:1169-1181 The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-hodgkin
More informationClinical characteristics and outcomes of primary bone lymphoma in Korea
VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Clinical characteristics and outcomes of primary bone lymphoma in Korea So Yeon Kim 1,#, Dong-Yeop Shin 1,#, Seung-Sook
More informationDownloaded from by guest on 18 November 2018
Radiation Protection Dosimetry Vol. 105, No. 1 4, pp. 581 586 (2003) Published by Nuclear Technology Publishing 2003 Nuclear Technology Publishing ASSESSMENTS FOR HIGH DOSE RADIONUCLIDE THERAPY TREATMENT
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationJOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
More informationORIGINAL ARTICLE. Keywords Relapse/refractory. DLBCL. Immunochemotherapy. Introduction
Ann Hematol (2015) 94:803 812 DOI 10.1007/s00277-014-2271-1 ORIGINAL ARTICLE Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationHigh incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens
original article 20: 309 318, 2009 doi:10.1093/annonc/mdn629 Published online 7 October 2008 High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationDosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAutologous hematopoietic stem-cell transplantation in lymphoma
MASTER S THESIS - KU LEUVEN Autologous hematopoietic stem-cell transplantation in lymphoma A single center experience Camille Kockerols Master of medicine 216-217 Supervised by Prof. Dr. D. Dierickx (first
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationAdvances in the management of follicular lymphoma
Hematology Meeting Reports 2007; 1(5):43 51 Advances in the management of follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland, Oncologia medica, Bellinzona, Switzerland Corresponding
More informationManaging Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options Fernando Cabanillas (Chair), Sandra Horning, Mark Kaminski, and Richard Champlin The front-line management of stage
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationPrognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin s lymphoma autografted after a first relapse
Original article Annals of Oncology 16: 625 633, 2005 doi:10.1093/annonc/mdi119 Published online 28 February 2005 Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lympoma Non-Hodgkin s Lymphomas Janet H. Van Cleave MSN, ACNP-CS, CS, AOCN Acute Care Nurse Practitioner The Mount Sinai Medical Center of New York City Doctoral Student, Yale University
More informationNon-Hodgkin lymphomas (NHLs) constitute a heterogeneous. Original Articles
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS Volume 28, Number 5, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/cbr.2012.1387 Original Articles Phase I Study of a Modified Regimen of 90 Yttrium Ibritumomab
More informationAPPROXIMATELY 50% of patients with non-
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin s Lymphoma By J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez,
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More information